從競爭分析模式觀點探討影響台灣生技醫藥技轉/授權廠商的關鍵成功因素

Abstract

全球的生命科學在電腦與資訊的帶動下，不僅有突破性的進展，更被視為21世紀的「顯學」，然而生技產業涵蓋的範圍極廣，以其中與人類健康福祉關係密切，且產值又大的生技醫藥業尤為引人矚目。

即使生技醫藥研發具備了研發時程長，且高投資、高風險等多項特質，但該產業所創造出的龐大價值與商機，仍吸引了世界各國相繼投入；相形之下，台灣的起步晚，發展條件也與許多國家相去甚遠，因此在面對全球的生技產業價值鏈日益密的情況，台灣應該如何定位，有哪些競爭優勢，而本土廠商在發展策略上，又該如何突破，特別是技轉與授權方面，以創造屬於台灣生技醫藥產業的利基，進而成為成功案例？

本研究主要目的在探討台灣上市櫃生技醫藥技轉與授權廠商之競爭力，以及與生技醫藥廠商關鍵成功因素之間的關係，並經由數個個案的競爭優勢(力)比較、分析、訪談及問卷內容歸納，期研究結果將可提供台灣生技醫藥廠商參考以因應技術與產業環境變化，並謀求最大競爭力，同時創造企業最大之價值與市場獲利機會。

本研究最後提出結論與建議，本土生技醫藥廠商雖受限於國內市場狹小，不易建立規模經濟及品牌，但因中小企業型態可靈活採用營運策略組合，若能輔以亞洲特有疾病與藥品為利基產品或市場方向，加上運用開放性創新或開放性發展策略如跨國策略聯盟或研發合作，將有助於加速研發速，增加企業成功機率。

With the help of advanced computer technology and information science, life science is making a great deal of breakthroughs in the past decade. The promise of life science has drawn more attention than before, especially in the field of biopharmaceuticals. Biopharmaceuticals does refer to a lot of people’s concerns, such as healthcare, quality of life, and huge market value, etc.

Bbiopharmaceutical R&D is quite unique. A new drug usually takes at least 10 years from bench to bedside. In addition, biopharmaceutical industry is also known as its high investment and high risk. Even so, biopharmaceuticals is still one of the most innovative and productive areas, with leading countries and big biotech/pharma companies spending considerable efforts for commercial applications. In Taiwan, due to the limit of domestic market size and the challenges of globalization, biopharmaceutical industry cannot help to face some transformations both in business model and development strategy.

The objective of thesis is to explore the competitiveness and key success factors of Taiwan’s biopharma companies in technology transfer and licensing out products through the competitive analysis model. Besides to collect and analyze primary and secondary information, the thesis focuses the correlation between two Taiwan public company cases in seven analytic factors, such as organization, finance, research, marketing, market demand and supply, global strategy, and government policy.

The thesis concludes with several suggestions for Taiwan's biopharma companies. In spite of disadvantages in market size and brand building, domestic biopharma company should have a more flexible strategy combination of management and business development. It definitely will enhance remarkably the opportunity of success if the company is able to aim for a niche market by way of open innovation in R&D, or strategic alliance with oversea companies.